Breast Cancer
Conditions
Brief summary
Foreign data show that: 1807 tumor patients were followed up for 7 years, 33% of them died of heart disease and 51% of them died of the tumor itself. In China, the number of cancer patients undergoing chemotherapy is increasing rapidly every year. How to protect the heart of chemotherapy patients from the damage of chemotherapy drugs (especially anthracyclines) is a problem that clinicians must face.In order to further confirm the clinical efficacy and value of saffron total glycosides tablets in the protection of central function of breast cancer neoadjuvant patients with anthracycline based chemotherapy scheme, the project plans to follow up and observe the research of saffron total glycosides on the protection of cardiac function of breast cancer neoadjuvant patients with chemotherapy based on cardiac color ultrasound combined with myocardial zymography, and randomly group to confirm the effectiveness of saffron total glycosides tablets on cardiac protection, Based on the clinical observation and research on the effect of traditional Chinese medicine on the cardiotoxicity of anthracycline drugs, confirm its efficacy, explore the mechanism of cardiac protection, and explore the drug use method of synergism and toxicity reduction of anthracycline drugs in combination with this active ingredient.
Detailed description
At present, the commonly used anthracycline antineoplastic drugs in clinic include daunorubicin, doxorubicin, epirubicin, pirarubicin, idabicin, pentarubicin and mitoxantrone, among which doxorubicin is one of the most commonly used antineoplastic drugs. However, anthracyclines have dose dependent and cumulative cardiotoxicity. In patients receiving doxorubicin (DOX) treatment, nearly 10% of patients will have cardiac complications after stopping chemotherapy for nearly 10 years, and its cardiac toxicity may even threaten life, which limits its clinical application. Crocus sativus glycoside, as the main active ingredient of Crocus sativus L., has a wide range of pharmacological effects, and it has a good effect on cardiovascular system. Based on the clinical observation and research on the effect of traditional Chinese medicine on the cardiotoxicity of anthracycline drugs, confirm its efficacy, explore the mechanism of cardiac protection, and explore the drug use method of synergism and toxicity reduction of anthracycline drugs in combination with this active ingredient. In this study, 120 patients with breast cancer undergoing neoadjuvant chemotherapy (including anthracycline) were randomly enrolled, and the cardiac baseline assessment was done. The clinical efficacy of crocin in protecting heart function of breast cancer patients undergoing neoadjuvant chemotherapy was evaluated according to clinical symptoms, cardiac color ultrasound, electrocardiogram and myocardial enzyme spectrum, To further verify the clinical application value and social and economic benefits of saffron, the heart protecting active ingredient in saffron, in the aspect of heart protection in neoadjuvant chemotherapy for breast cancer, and further promote the use and broaden the clinical application range of traditional Chinese medicine. Prevention is more important than treatment, which is in line with the national concept of preventing disease of traditional Chinese medicine.
Interventions
DRUGCrocin
According to the patient's condition, tolerance level, and personal preference, the dosage of medication was selected. During chemotherapy, the total anthocyanin tablets were divided into an experimental group (experimental group 1 and experimental group 2 based on previous heart disease) and a control group (control group 1 and control group 2 based on previous heart disease), 30 cases in each group \[experimental group: taking saffron total glycoside tablets for 8 days during each chemotherapy period (starting from the day before chemotherapy), 4 tablets/time, 3 times a day; control group: not taking saffron total glycoside tablets during chemotherapy period\]
Sponsors
Mei Zhang
Study design
Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
FEMALE
Age
20 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Female patients with breast cancer aged ≥ 20 years and ≤ 80 years, with informed consent and meeting the treatment standard of neoadjuvant chemotherapy scheme. 2. Patients who plan to receive neoadjuvant chemotherapy based on anthracycline drugs (such as erythromycin, doxorubicin, epirubicin, pyranomycin, idabicin, pentorubicin, and mitoxantrone). 3. No treatment for breast cancer before enrollment, such as chemotherapy, targeted therapy and endocrine therapy. 4. All patients underwent coarse needle biopsy of breast tumors (axillary lymph node biopsy is required for suspected axillary lymph node metastasis) to determine the status of ER, PR, HER-2, and Ki-67. 5. All patients have normal lung function, liver and kidney function.
Exclusion criteria
1. Cases that do not cooperate and are unwilling to sign informed consent forms. 2. Antitumor therapy, hormone replacement therapy and other breast cancer related treatments were performed before enrollment. 3. Merge any other malignant tumors. 4. Patients with poor image quality in echocardiography. 5. Continuous atrial fibrillation and severe arrhythmia affect ultrasound data collection and analysis. 6. Patients with active infections, a history of HIV, or chronic hepatitis B or C. 7. Patients with abnormal lung function or liver and kidney function. 8. Patients with hemorrhagic diseases. 9. Patients taking other heart protection traditional Chinese patent medicines and simple preparations. 10. Participated in other clinical researchers in the past 3 months.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cardiac ultrasound LVEF, GLS | December 2024 | LVEF and GLS levels measured by echocardiography before and after treatment (within and between groups). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Abnormal rate of electrocardiogram | December 2024 | Comparison of abnormal electrocardiogram rates before and after treatment (within and between groups). |
| Overall radial strain of the heart | December 2024 | Overall radial strain measured by ultrasound before and after treatment (intra group and inter group). |
| Cardiac asynchrony index | December 2024 | Cardiac asynchrony index before and after treatment (within and between groups). |
| myocardial enzymes | December 2024 | Comparison of myocardial enzyme spectrum results before and after treatment (within and between groups). |
| Symptoms of cardiac discomfort | December 2024 | The frequency and duration of chest tightness, chest pain, and palpitations. |
Countries
China
Outcome results
None listed